Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Pregnenolone sulphate is a naturally occurring neurosteroid, synthesized in the body from pregnenolone through sulfation. It acts in the central nervous system as a potent negative allosteric modulator of GABAA receptors and as a weak positive allosteric modulator of NMDA receptors. Pregnenolone sulphate is also known to modulate AMPA, kainate, and glycine receptors (typically via negative modulation), and may interact with nicotinic acetylcholine receptors. Additionally, it is an agonist of the sigma receptor and an activator of the TRPM1 and TRPM3 ion channels. It exhibits cognitive- and memory-enhancing, antidepressant, anxiogenic, and proconvulsant effects[1][3][6]. Its roles have been studied largely in the context of neurobiology, inflammation, and neuroprotection[3][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on pregnenolone sulphate.